Enliven Therapeutics logo
Enliven Therapeutics
ELVN | NASDAQ
Chart Builder DCF Calculator
$47.62
-$1.18 (-2.42%)
At close: Nov 16, 2026, 4:00 PM ET
$47.62
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Enliven Therapeutics Company Profile

Company profile explained

Company Profile

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Key Executives

Name Position
Richard A. Fair CEO, President & Director
Anish Patel Co-Founder & Chief Operating Officer
Benjamin Hohl Chief Financial Officer & Head of Corporate Development
Galya D. Blachman Chief Legal Officer & Head of Business Development
Damiette Smit Vice President of Clinical Development
Helen Louise Collins Chief Medical Officer
Joseph Lyssikatos Co-Founder & Research Fellow
Samuel S. Kintz Co-Founder & Head of Pipeline

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 21, 2026 4 Filing
Oct 21, 2026 4 Filing
Oct 16, 2026 4 Filing
Oct 16, 2026 3 Filing
Oct 14, 2026 8-K Current Report
Oct 05, 2026 4 Filing
Sep 21, 2026 4 Filing
Sep 21, 2026 4 Filing
Aug 19, 2026 4 Filing
View All SEC Filings ➞
Enliven Therapeutics
Enliven Therapeutics logo
Country United States
IPO Date Mar 12, 2020
Industry Biotechnology
Sector Healthcare
Employees 67
CEO Richard A. Fair

Contact Details

6200 Lookout Road Boulder, Colorado 80301 United States

Stock Details

Ticker Symbol ELVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001672619
CUSIP Number 29337E102
ISIN Number US29337E1029
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.